macitentan
Also known as ACT-064992, ACT064992, ACT 064992
Macitentan, sold under the brand name Opsumit, is an endothelin receptor antagonist developed by Actelion and approved for the treatment of pulmonary arterial hypertension (PAH). Macitentan is a dual endothelin receptor antagonist, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ETA and ETB. However, macitentan has a 50-fold increased selectivity for the ETA subtype compared to the ETB subtype.
Wikidata facts
- Mass
- 585.9633483200003
Show 5 more facts
- chemical formula
- C₁₉H₂₀Br₂N₆O₄S
- canonical SMILES
- CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br
- World Health Organisation international non-proprietary name
- macitentan
- defined daily dose
- 10
- Commons category
- Macitentan
~4 min read
Article
7 sectionsContents
- Adverse effects
- Mechanism of action
- Endothelin and endothelin receptors
- Role of macitentan
- Pharmacokinetics
- Experimental pharmacokinetics
- References
Macitentan, sold under the brand name Opsumit, is an endothelin receptor antagonist developed by Actelion and approved for the treatment of pulmonary arterial hypertension (PAH). Macitentan is a dual endothelin receptor antagonist, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ETA and ETB. However, macitentan has a 50-fold increased selectivity for the ETA subtype compared to the ETB subtype.
Macitentan was approved for medical use in the United States in October 2013.
Available in 11 languages
via Wikidata sitelinks · CC0